Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...